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Abstract
Bone metastases have a devastating impact on quality of life and bone pain in patients with prostate cancer and
decrease survival. Animal models are important tools in investigating the pathogenesis of the disease and in de-
veloping treatment strategies for bone metastases, but few animal models recapitulate spontaneous clinical bone
metastatic spread. In the present study, IGR-CaP1, a new cell line derived from primary prostate cancer, was stably
transduced with a luciferase-expressing viral vector to monitor tumor growth in mice using bioluminescence
imaging. The IGR-CaP1 tumors grew when subcutaneously injected or when orthotopically implanted, reconstituted
the prostate adenocarcinoma with glandular acini-like structures, and could disseminate to the liver and lung. Bone
lesions were detected using bioluminescence imaging after direct intratibial or intracardiac injections. Anatomic
bone structure assessed using high-resolution computed tomographic scans showed both lytic and osteoblastic
lesions. Technetium Tc 99m methylene diphosphonate micro single-photon emission computed tomography con-
firmed the mixed nature of the lesions and the intensive bone remodeling. We also identified an expression signature
for responsiveness of IGR-CaP1 cells to the bone microenvironment, namely expression of CXCR4, MMP-9, Runx2,
osteopontin, osteoprotegerin, ADAMTS14, FGFBP2, and HBB. The IGR-CaP1 cell line is a unique model derived from
a primary tumor, which can reconstitute human prostate adenocarcinoma in animals and generate experimental
bone metastases, providing a novel means for understanding the mechanisms of bone metastasis progression
and allowing preclinical testing of new therapies.
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Introduction
Prostate cancer (PCa) is the most commonly diagnosed cancer in men
in the Western world and is the second leading cause of male cancer
deaths [1]. PCa has a high propensity to metastasize to bone, and
virtually all patients who die of PCa have bone metastases [2]. Pa-
tients with bone metastases experience severe pain, nerve compression
syndromes, and pathologic fractures. PCa that has metastasized to bone
remains incurable, and in most patients, a fatal outcome is linked to
bone metastases rather than to the primary tumor [3]. Although bone
metastases are particularly difficult to target, the knowledge of tumor
progression and metastasis has recently improved with the emergence
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of new bone-specific therapies. However, the survival benefit of these
new bone-specific agents is unclear, and understanding the mechanisms
of tumor metastasis remains a challenge. These challenges are obstacles
to improving cancer treatment and prognosis.
Under normal conditions, bone undergoes continuous remodeling
in a tightly coordinated and balanced process of osteoclast-mediated
bone resorption and osteoblast-mediated bone formation. The skeletal-
related events associated with bone metastasis are mediated by an im-
balance between osteoblasts and osteoclasts that is induced by tumor
cells [4,5]. Prostate tumor cells in the bone environment begin to
secrete several factors associated with bone remodeling. Some of
these factors have osteogenic properties, including the bone morpho-
genetic proteins and endothelin 1. Other factors, such as parathyroid
hormone–related protein, trigger inhibition of osteoblast growth.
Additional factors indirectly enhance bone production (e.g., transform-
ing growth factor β), enhance osteosclerosis (e.g., osteoprotegerin
[OPG]) or directly initiate osteoclastogenesis (e.g., receptor activator
of nuclear factor κB [RANK] and RANK ligand [RANKL]). In PCa,
bone metastases are primarily osteoblastic; however, high bone turn-
over and consequent excessive bone resorption are also characteristic
features of the disease [6].
The molecular mechanisms underlying the bone tropism of PCa
metastasis remain unclear. This gap in knowledge is partly due to
difficulties both in obtaining metastatic tissue from patients and in
generating mouse models that display bone metastasis. Preclinical
models are needed to investigate this mechanism and to constitute a
useful niche for proof of concept in preclinical evaluations of new
therapies. The most popular current models are the PC-3, LNCaP,
and DU145 cells and their derived sublines. Although these cell line
models represent a major advance in the field of PCa research, they have
several inherent drawbacks. In particular, the multistep development
of cancer in xenografts remains far from the physiologic reality because
most xenografted tumors and tumor cell lines selectively represent the
histologic diagnosis and the metastatic patterns of human tumors at
an advanced stage. Moreover, few in vivo models mimic the natural
progression and dissemination of PCa. For example, the PC-3 pre-
clinical model generates only osteoclastic lesions [7]. Indeed, few
models reproduce osteoblastic or mixed osteolytic/blastic lesions when
implanted in the bones of immunocompromised mice, corresponding
to the most frequent phenotype in patients. To date, these models
are limited to the LNCaP-derived C4-2B, LuCaP 23.1, LAPC9,
MDA-PCa-2b, VCaP, and 22Rv1 preclinical models [8–17]. Dy-
namically monitoring the metastatic development with imaging tech-
nology, such as bioluminescence imaging (BLI), currently provides
a tremendous advantage for studying bone metastases in xenograft
models. The luciferase-expressing PC-3–derived cell lines were the
most widely used models [18]. However, the availability of luciferase-
expressing models to achieve the follow-up of bone metastasis devel-
opment using BLI remains quite limited to other models. Indeed,
some of these models cannot be grown in culture as LAPC9 and
LuCaP series. Thus, new animal models that more closely mimic the
human disease are required for a better understanding of the molecular
mechanisms of PCa bone metastasis and preclinical research.
Unlike many other cell lines that have been obtained from prostate
tumor metastases, the IGR-CaP1 cell line was established from a
localized epithelial PCa, which makes it a better model to reflect the
mechanisms of tumor progression from localized cancer to metastatic
disease. In this report, we describe the establishment of the new
IGR-CaP1 preclinical model, which can reconstitute human prostate
adenocarcinoma in animals. We have engineered these cells to express
firefly luciferase for visualizing the development of metastases and
showed that this model grew in bone after either intratibial injection
or inoculation of cells into the left cardiac ventricle of nude mice. We
identified a signature of genes that are overexpressed in tumor cells
during the bone remodeling process. Thus, this model provides a novel
means for identifying and understanding mechanisms that contribute
to bone metastasis and allows for preclinical testing of new anticancer
therapies, specifically bone-targeting therapies.
Materials and Methods
Cell Lines
The human androgen-independent IGR-CaP1 cell line was established
in the laboratory from a primary PCa [19]. PC-3 cell line was purchased
from ATCC-LGC (Molsheim, France). Cells were grown in RPMI
medium containing 10% fetal bovine serum (PAA Laboratories, Les
Mureaux, France) and antibiotics under standard culture conditions.
Retroviral Vector Production and Transduction of
IGR-CaP1 Cells
To obtain the IGR-CaP1-Luc cells, we used a retrovirus express-
ing the luciferase gene (pMEGIX-Luc vector), kindly provided by
Dr J.L. Villeval (UMR 1009; Villejuif, France), carrying an expres-
sion cassette encoding the firefly luciferase and green fluorescent pro-
tein (GFP) genes separated by an internal ribosomal entry site. The
Luc-GFP viruses were produced by transient transfection of 293T
cells according to standard protocols [20]. Briefly, subconfluent
293T cells were cotransfected with 20 μg of the luciferase-expressing
plasmid vector, 13 μg of pCMV-Gag-Pol, and 7 μg of pVSVG by
calcium phosphate precipitation. After 16 hours, the culture medium
was changed, and the recombinant retrovirus was harvested 48 hours
later. For transduction, viruses were added to cells for 24 hours.
The GFP-positive IGR-CaP1 luciferase-expressing cells were sorted
for green fluorescence using a MoFlo cell sorter (Beckman-Coulter,
Miami, FL) before amplification.
Animal Tumor Models
All animal experiments were approved by the local ethics com-
mittee (CEEA IRCIV/IGR no. 26, registered with the French Min-
istry of Research) and were in compliance with EU Directive 63/
2010. IGR Animal Resources holds a National Institutes of Health–
Department of Health and Human Services Animal Welfare Insurance
(no. A5660-01) and is in compliance with the Guide for the Care and
Use of Laboratory Animals. Six-week-old male athymic nude mice
(NC-nu/nu) were purchased from Janvier (Le Genest-St-Isle, France).
IGR-CaP1 cells (107) were implanted subcutaneously in the right rear
flank region of nude mice without Matrigel. For orthotopic injections,
IGR-CaP1-Luc cells (106) in 20 μl of phosphate-buffered saline (PBS)
were injected after exposure into the prostatic lobe at the base of the
seminal vesicles through a midline laparotomy incision as previously
described [15]. Tumor size resulting from subcutaneous xenograft
was measured with calipers. The following formula was used to cal-
culate tumor volumes: V = л/6 × L × l 2, where L is the length of
the longest aspect of the tumor and l is the length of the tumor
perpendicular to L. Bioluminescence imaging was used to follow the
tumor growth of intraprostatic tumors. The mice were killed, and tu-
mors were excised and measured.
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Experimental Metastasis Model
For the intratibial and intracardiac injections, mice were main-
tained under isoflurane anesthesia during the injection procedure. A
29-gauge needle was inserted extracapsulary through the tibial crest,
the epiphysis, and the growth plate. IGR-CaP1-Luc cells (5 × 105 cells
in 100 μl of PBS) were injected in the bone marrow space of the
right tibia. The left tibias were either not injected or injected with
PBS alone as precise to serve as controls and to evaluate the effect of
injection trauma on bone remodeling. Animals were monitored the
day after injection and for 5 weeks after injection of IGR-CaP1-Luc
cells. After the mice were killed, the tumors and contralateral tibias were
harvested. For intracardiac injections, IGR-CaP1-Luc cells (5 × 105)
were suspended in 100 μl of 5% sterile glucose solution and were
injected into the left ventricle using a 29-gauge needle after confirma-
tion of the location of the tip of the needle in the left ventricle as indi-
cated by pulsatile blood flow in the hub of the needle. Animals were
monitored the day after injection and for 5 weeks after injection of
IGR-CaP1-Luc cells.
Bioluminescence Imaging
Mice were injected intraperitoneally with D-luciferin potassium salt
(Caliper Life Sciences, Hopkinton, MA) (15 mg/ml in sterile water)
15 minutes before being imaged. The mice were anesthetized with
2% isoflurane and were imaged in dorsal and ventral positions using
an IVIS 50 cooled charge-coupled device camera system (Caliper Life
Sciences) to monitor tumor growth and metastases dissemination.
After acquiring a grayscale photograph, a bioluminescent image was
obtained with a 12-cm field of view, a binning (resolution) factor of
8, and a 1/f stop-and-open filter. Regions of interest were defined
manually (using a standard area in each case), and signal intensities
were calculated with Living Image software (Caliper Life Sciences)
and expressed as photons per second. Background photon flux was
defined from a region of interest drawn over a control.
Micro X-ray Computed Tomography
Mice were anesthetized with a mixture of ketamine (100 mg/kg)
and xylazine (10 mg/kg) and were imaged using a micro–computed
tomography (CT 120; General Electric, Buc, France). During imaging,
360-degree x-ray projections were collected in 1-degree increments
(80 kVp, 450 μA, 120 milliseconds of exposure time for approximately
25 minutes of total scan time). Projection images were preprocessed
and reconstructed into three-dimensional volumes (10,243 voxels;
resolution, 93 μm) on a four-PC reconstruction cluster using a modified
tent-FDK cone beam algorithm (GE reconstruction software). Three-
dimensional data were processed and rendered (isosurface/maximum
intensity projections) usingMicroView (GEHealthcare,Milton, Canada).
Data analysis was performed first on individual slices (axial, coronal,
and sagittal) and then on three-dimensional reconstructed volumes.
Single-Photon Emission Computed Tomography
Methylene diphosphonate (MDP) is a conventional bone scintigraphy
agent widely used for functional imaging of bone remodeling, which
reflects bone blood flow and osteoblastic activity. MDP is tagged with
technetium Tc 99m to generate 99mTc-MDP, which selectively con-
centrates in the bone via its chemical adsorption to the crystalline
structure of hydroxyapatite. Mice were injected in the tail vein with
18 MBq of 99mTc-MDP, and images were recorded 60 minutes after
injection. Mice were anesthetized with 1.5% to 2% isoflurane in oxy-
gen and were transferred onto the warmed bed of a NanoSPECT/CT
(Bioscan, Washington, DC), a small animal imaging system based on
multiplexed multipinholes technology to preserve both sensitivity and
resolution. This device incorporates parallel helical CT scanning. Image
acquisition parameters were 24 projections and 30 to 60 sec/image,
depending on the activity. A dedicated software (InVivoScope 1.39)
was used to reconstruct three-dimensional single-photon emission
computed tomography (SPECT)/CT fusion images and to quantify
radioactivity. Image analysis was performed both qualitatively by com-
paring the fusion images with bioluminescence and CT data and
quantitatively by assessing radioactivity in volumes of interest drawn
around tumors in both legs. The results are expressed as percent of
injected doses. P < .05 was considered statistically significant.
Immunohistochemistry
After imaging, the tissue specimens were collected and fixed in
Finefix (Milestone Medical, Bergamo, Italy). The fixed skeleton spe-
cimens were decalcified with the Sakura TDE 30 decalcifier system
(Sakura, Japan) for 30 to 90 minutes, according to the type of bone.
Decalcified femur, tibia, skull, and the lower half of the spine were
embedded in paraffin after tissue processing. All long bones were cut
sagittally and along a longitudinal axis through the center of each
bone. The spines were cut along the anterior-posterior axis. Skulls
were also sagittally dissected from the midline. Serial 4-μm paraffin
sections were processed and routinely stained with hematoxylin-eosin-
safranin (HES). Tumor and organ sections were incubated with mouse
monoclonal antivimentin (clone V9; Dako, Trappes, France), rabbit
polyclonal anti-P504S/AMACR (Diagnostic BioSystems, Nanterre,
France), rat antimouse CD34 antibody (1:20; Hycult Biotechnol-
ogy, Nanterre, France), mousemonoclonal anti-Runx2 (27-K; Santa Cruz,
Nanterre, France), or rabbit polyclonal anti–MMP-9 (Cell Signaling,
Saint Quentin Yvelines, France) antibodies. Immunostaining was visu-
alized using rabbit or mouse PowerVision Kit (ImmunoVision Tech-
nologies, Burlingame, CA). Immunohistologic signals were finally
revealed with the peroxidase/diaminobenzidine chromogenic substrate.
All sections were analyzed using a Zeiss Axiophot microscope (Zeiss,
Oberkochen, Germany), and images were acquired with a SensiCam
PCO digital camera (PCO, Kelheim, Germany).
TaqMan Real-time Quantitative Reverse Transcription–
Polymerase Chain Reaction Analysis
Reverse transcription–polymerase chain reaction (RT-PCR) was per-
formed to confirm the expression of bone metastasis–specific markers
in intratibial-injectedmice. Total RNAwas extracted from bone (9 weeks
after inoculation) or tumors tissues (27 weeks after inoculation) using
the TriReagent protocol (Invitrogen-life Technologies, Saint Aubin,
France), and 5 μg of RNA was reversed transcribed using random
hexamers (Applied Biosystems-life Technologies, Saint Aubin, France).
Quantitative RT-PCR was performed with the ABI Prism 7900
Sequence Detection System (Applied Biosystems) using 5 μl of 1:20
diluted complementary DNA in a final volume of 25 μl according to the
manufacturer’s recommendations. The primer/probe sets were obtained
from Applied Biosystems (HBB, Hs00758889_s1; TNFRSF11B/
OPG, Hs00900358_m1; SPP1/osteopontin, Hs00959010_m1;
CXCR4, Hs00607978_s1; ADAMTS14, Hs01548449_m1;
FGFBP2, Hs00230605_m1) and were used according to the manufac-
turer’s recommendations. The amount of sample RNA was normalized
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to the amplification of an internal human control (GAPDH-435293E;
Applied Biosystems). In each experiment, the relative quantification of
the transcripts was derived using the ΔΔCT method and was expressed
relative to the Universal Human Reference RNA (Agilent Technolo-
gies, Massy, France). The results were compared with the results from
total RNA extracted from subcutaneous xenografts.
Results
Time Course Progression of IGR-CaP1 Tumors
Tumors grew after subcutaneous injection of IGR-CaP1 cells in
athymic nude mice (Figure 1A). Subcutaneous xenografts were pal-
pable 2 weeks after injection, with a tumor take of 100% (20 mice).
Tumors started to grow at week 3; tumors of ∼300 mm3 were ob-
tained after 6 weeks, and they reached a maximum size of ∼500 mm3
after 15 weeks.
In an effort to specifically follow the tumor growth of intraprostatic
tumor noninvasively via BLI, we generated a luciferase- and GFP-
expressing IGR-CaP1 cell line by retroviral transduction. Forty-eight
hours after transduction, GFP-positive cells were sorted and ampli-
fied. GFP-positive, luciferase-expressing cells were inoculated into the
prostate of nude mice, and tumor growth was followed for 40 weeks
using BLI. The tumor take was 84% (28/33 mice). The mice were
scanned every 3 to 4 weeks. In a group of nine implanted mice, we
observed a slow increase in bioluminescence activity that was signifi-
cant 9 weeks after inoculation and reached a plateau after 30 weeks
(Figure 1, B and C ). Prostate tumors were confirmed after excision
from the euthanized animal at the end of the experiment. At 40 weeks
after engraftment in the prostate, the tumor size reached to a maxi-
mum of 500 mm3. Whereas the IGR-CaP1 cells grew quickly in vitro,
the tumor growth rate was slower in the animals, especially in ortho-
topically implanted tumors. This situation most closely reflects the slow
clinical progression of PCa.
Reconstitution of Prostate Adenocarcinoma
PC-3 cells are the most commonly used PCa model able to mimic
bone metastases [21]. These cells produce highly tumorigenic non-
differentiated tumors by 4 weeks when injected subcutaneously.
Compared with PC-3 cells with inconspicuous stromal regions, the
IGR-CaP1 cells produce more differentiated tumors with glandular
acini-like structures suggestive of adenocarcinoma (Figure 2A, insert
and arrows). After direct injection of IGR-CaP1 cells into the pros-
tate, orthotopic tumors were relatively undifferentiated but retained
acinar structures and abundant stroma, exhibiting areas of poorly
Figure 1. Progression of IGR-CaP1 tumors in animals. (A) Tumor progression of subcutaneously implanted IGR-CaP1 cells in nude mice
(n = 20). Tumor growth was monitored weekly using caliper measurement. (B) Bioluminescent imaging time course of orthotopically
inoculated GFP- and luciferase-expressing IGR-CaP1 cells. Nine mice were imaged monthly to monitor tumor growth. For A and B, the
curves correspond to the adjustment of the logistic regression model on the average of the observed values at each time point, and
results are expressed as the mean ± SEM. (C) A representative mouse with intraprostatic tumor monitored by BLI showing a metastatic
site at week 28.
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differentiated carcinoma with a high Gleason score (Figure 2B). The
endothelial cell marker CD34 was used to determine microvessel den-
sity of the tumor [22]. As shown using CD34 immunohistochemical
staining, the IGR-CaP1 tumors were highly vascularized. The CD34
labeling was heterogeneous and mostly localized in the stromal areas
(Figure 2B). Immunostaining for CD34 was previously observed in
prostate tumors, reflecting an increased density of capillaries in invasive
prostate cancer [23]. The tumorigenicity of IGR-CaP1 tumors, which
was previously shown with Ki67 proliferation marker [19], was con-
firmed by strong expression of the vimentin invasion marker, which
was mainly detected in poorly differentiated prostate cancer and bone
metastases [24]. Labeling of epithelial cells with the prostate markers
corresponding to P504S/AMACR confirmed the prostate origin of
the tumor (Figure 2B). Taken together, the IGR-CaP1 tumors re-
capitulated the characteristics of aggressive prostate adenocarcinoma
with a microenvironment similar to its human counterpart.
IGR-CaP1 Metastases Spread to Soft Organs
IGR-CaP1 cells formed tumors with high incidence either when
administered subcutaneously or when orthotopically implanted in
intact or castrated athymic male mice [19]. Although detected at low
frequency, both subcutaneously and orthotopically injected IGR-CaP1
cells disseminated to distant organs, such as liver (20%, 2/10 mice),
lung (20%, 2/10 mice), and the kidney and peritoneal cavity (40%,
4/10 mice) and were confirmed histologically. Figure 3A shows a
large metastasis found in the liver with a weak expression of the prostate
marker P504S and strong expression of vimentin. A small metastasis
in the lung with high vimentin expression is also shown (Figure 3B).
Because the matrix metalloproteinase (MMP-9) is critical for the for-
mation of the metastatic niche [25], we assessed MMP-9 expression
in IGR-CaP1 metastases. As shown in Figure 3A, we observed high
expression of MMP-9 in the liver metastasis. Thus, this result is con-
sistent with previous data showing that increased expression of MMP-9
Figure 2. IGR-CaP1 tumors reconstitute prostate adenocarcinoma. IGR-CaP1 cells were injected into mice both subcutaneously (A) or
intraprostatically (B). Magnification, ×50; insert, ×400. (A) Comparison of HES staining of tumor sections between IGR-CaP1 and PC-3
tumors revealed a glandular differentiation with acini (shown with arrows and in insert) in IGR-CaP1 tumor that is absent in PC-3 tumors.
(B) HES staining of tumor sections of orthotopically implanted IGR-CaP1 cells showed more undifferentiated tumors with abundant
stroma. Immunohistochemical staining of the endothelial cell marker CD34 showed a high microvessel density within the stromal re-
gions. Vimentin (VIM) revealed the invasive potential of the tumor. Markers corresponding to AMACR (P504S) confirmed the prostate
origin of the tumor. Magnification, ×100; inserts, ×400. Arrows indicate the presence of acini and asterisks show stromal regions.
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is associated with higher-grade local PCa, disease recurrence, and
metastatic PCa [26,27].
Intensive Bone Remodeling after Direct Injection into Bone
Bone is the main site of metastases of PCa. Compared with lesions
observed in lung or breast cancer, PCa bone metastases are mainly
osteoblastic. However, high bone turnover and consequent excess
bone resorption are also characteristic features [28]. We evaluated the
ability of the luciferase-expressing IGR-CaP1 cells to generate bone
metastases using BLI and high-resolution CT. We did not detect
spontaneous metastases in bone from subcutaneous or orthotopic
IGR-CaP1 xenografts up to 10 months after engraftment. However,
after direct intraosseous implantation of luciferase-expressing IGR-
CaP1 cells into the tibia, we observed major bone lesions 10 weeks
after injection in 86% of mice (6/7), visualized with three-dimensional
isosurface renderings from CT scan (Figure 4A, left). Study of the indi-
vidual slices confirmed bone remodeling in the injected tibias compared
with control tibias (Figure 4A, right). Indeed, the sagittal views consis-
tently showed both lytic lesions in the cortical bone and osteoblastic
lesions in the trabecular bone. SPECT using radionuclides is used
to investigate bone metastases in PCa patients and provides detailed
information about the anatomy and physiologic state of the bone. Bone
SPECT with 99mTc-MDP is the initial method of choice to detect
skeletal metastases in cancer patients [29]. 99mTc-MDP accumulates
in the bone by chemical adsorption and incorporation into the hydroxy-
apatite structure [30]. The uptake of 99mTc-MDP was investigated
after direct injection of IGR-CaP1 cells in the tibia and confirmed the
mixed nature of the lesions and the intensive bone remodeling, with
enhanced osteoblastic activity as indicated by a ∼five-fold increase
in 99mTc-MDP fixation in injected tibia versus control tibia (Mann-
Whitney U test, P = .0079; Figure 4B). Histologic examination
showed a massive invasion of cortical bone with tumor cells in the
injected tibia compared with the control tibia as confirmed by HES-
and trichrome-stained sections (Figure 4C). Vimentin-stained sections
Figure 3. IGR-CaP1 tumors spontaneously disseminate to soft organs. Spontaneous metastases were observed in several organs, at
week 31 after inoculation, as illustrated in the liver (A) and the lung (B). Metastases showed conserved expressions of invasive markers
VIM and MMP-9. The prostate marker P504S was also conserved in the metastases. Magnifications: A, ×100. B, HES, ×50; insert,
×200; Vim, ×100; insert, ×400.
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confirmed the presence of the tumor cells within the bone. The mixed
bone lesions were confirmed by the presence of both bone-resorbing
osteoclasts on the surface of newly deposited bone (Figure W1, A and
B) and the border of small osteoblasts lining bone trabeculae (Fig-
ure W1, C and D). These results are in contrast with the widely used
PC-3 preclinical model, which shows exclusively osteolytic activity
after bone injection [7,11,12]. Thus, the IGR-CaP1 cells were able to
generate bone lesions that closely resemble, at the bioimaging and
histopathologic level, prostate tumor bone metastases that are com-
monly encountered clinically.
Experimental IGR-CaP1 Bone Metastases
We examined the ability of luciferase-expressing IGR-CaP1 cells to
metastasize to bone using direct intracardiac injection of tumor cells
Figure 4. High levels of bone remodeling after direct injection of IGR-CaP1 cells into bone. IGR-CaP1 cells were injected into the bone
marrow of the mice. (A) Massive bone remodeling (arrow) was observed by CT 5 weeks after injection of IGR-CaP1 cells in the injected
tibia compared with the control noninjected tibia in 86% of mice and showed both osteolytic and osteoblastic activities. (B) The intense
bone remodeling was confirmed using SPECT by measuring the incorporation of 99mTc-MDP into the bone. Quantization of the relative
incorporation is shown (Mann-Whitney U test, P = .0079; n = 5). (C) Comparison of the injected tibia versus the control tibia by immuno-
histochemical staining is shown. HES staining and Masson blue trichrome staining show the remodeling within the bone marrow, visualiz-
ing newly synthesized osteoid (*). The expression of the invasive marker VIM was found both within the primary tumor and within the
metastases. Magnification, ×100.
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through the left cardiac ventricle in nude mice. This approach models
the hematogenous dissemination of cancer cells and allows examina-
tion of the process of metastatic colonization at various organ sites.
After their initial adhesion at the distant organ site, the disseminated
tumor cells must proliferate sufficiently to be detectable by BLI. The
bioluminescence was evaluated 5 weeks after inoculation. We eval-
uated the ability of the tumor cells to generate bone metastases using
BLI, CT scan, and 99mTc-MDP SPECT. Only those mice that showed
BLI signals at 5 weeks (5/9 mice) were selected for CT scan and SPECT
evaluation. Bioluminescence imaging revealed metastatic colonization
in bone, mostly in the mandible, femur, tibia, and vertebral column.
Representative mice (Figure 5A) show the different localization of
Figure 5. IGR-CaP1 cells generate bone metastases after intracardiac injections. IGR-CaP1 cells were injected into the left cardiac
ventricle. (A) Multiple bone metastases were observed using BLI 5 weeks after injection. A representative mouse showed the bone
localization of metastases. (B) CT scan acquisition and the incorporation of 99mTc-MDP measured with SPECT confirmed the presence
of bonemetastases in the mandible. (C) Histologic staining of decalcified bone sections confirmed the presence of bone lesions. As shown
with intratibial injection, metastases in limb were osteoblastic. All bone metastases showed intense VIM expression. Magnification, ×50;
insert, ×400. Arrows show the metastases.
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luminescence. The modification of the bone structure in the mandible
was observed using CT scan (Figure 5B, left), and uptake of 99mTc-
MDP revealed a two-fold increase in bone remodeling activity in the
altered side of the mandible (Figure 5B, right). Histologic analysis con-
firmed the invasion of tumor cells in the mandible, the hind limb, and
the vertebral column (Figure 5C ). The osteoblastic activity of IGR-
CaP1 cells was clearly evidenced in the hind limb, showing large re-
gions of newly woven bone. Osteoclastic activity was evidenced by the
presence of osteoclasts (Figure W2). All IGR-CaP1 tumor cells retained
a high expression of vimentin in the bone metastases (Figure 5C). In
total, all mice injected with luciferase-expressing IGR-CaP1 cells that
were imaged showed metastases in bone. Taken together, these results
indicate that intracardiac inoculation of luciferase-expressing IGR-CaP1
cells is a relevant model for studying homing of PCa cells and is a rare
model that can target mixed osteolytic/osteoblastic bone metastases.
Specific Human Bone Metastasis Signature in
IGR-CaP1 Model
Once established in bone, tumor cells interact with the bone micro-
environment in a reciprocal fashion via cytokine mediators to form
osteoblastic, osteolytic, or mixed lytic/blastic lesions. We determined
the expression of several genes that are frequently associated with bone
metastases in breast and prostate cancer to evaluate the relevance of
IGR-CaP1 as a model of human PCa bone metastases [31–34]. Gene
expression was determined using real-time quantitative RT-PCR on
total RNA directly extracted from IGR-CaP1–injected and control
PBS-injected tibias of nude mice and from subcutaneously xeno-
grafted tumors. We were able to detect an increased gene expression
of the hemoglobin B (HBB ), osteopontin (SPP1), OPG, ADAMTS14,
and FGFBP2 human genes in IGR-CaP1–injected tibias and in
tumors (Figure 6A). None of these genes were expressed in the control
Figure 6. The IGR-CaP1 model expresses a set of human bone metastasis genes. (A) The relative expression of specific human bone
metastasis genes in bone lesions was determined using real-time quantitative RT-PCR. Gene expression was detected in IGR-CaP1–
injected tibias (n = 7; gray bars) and IGR-CaP1–xenografted tumors (n = 4; black bars) but not in PBS-injected control tibias. The results
were normalized using the human GAPDH gene and were expressed relative to the universal reference RNA. (B) Immunohistochemical
staining showing expression of intracellular MMP-9 and nuclear Runx2 in either intraprostatic tumors (upper figures) or decalcified bone
sections (lower figures). Magnification, ×100; insert, ×400.
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PBS-injected tibias. ADAMTS14 was slightly underexpressed in the
parental IGR-CaP1 cell line (data not shown), whereasOPG was highly
up-regulated in mice-injected cells compared with the cell line level.
HBB and FGFBP2 were expressed at very low levels in IGR-CaP1 (data
not shown) and were highly overexpressed in bone and in tumors.
These genes were previously shown to be upregulated in metastatic
PCa samples [33–35]. Indeed, osteopontin (SPP1) was recently shown
as a prometastasis invasion gene in human PCa and belongs to the
four-gene signature of drivers of PCa progression [36]. SPP1 was found
to be highly expressed in bone and tumors (Figure 6A) and in IGR-
CaP1 cells (data not shown). Because the CXCR4/CXCL12 signaling
pathway plays a pivotal role in the process of distant site metastasis and
because we have previously shown that the IGR-CaP1 cells expressed
CXCR4 [19], we also measured the expression of the CXCR4 gene in
IGR-CaP1–-injected bone and tumors using RT-PCR (Figure 6A). We
detected CXCR4 expression in both bone lesions and tumors. How-
ever, the expression was not significantly different between these two
tissues. Furthermore, given the essential role of the transcription factor
Runx2 in osteogenesis and bone metastasis [37,38], we assessed the
expression level of Runx2 in our IGR-CaP1 mouse model using an
immunohistochemical approach. Because Runx2 directly activates the
transcription of genes encoding enzymes such as MMP-9, we also
assessed the expression of MMP-9 in intraprostatic tumors and bone
metastases by immunohistochemistry. Although the expression levels
of MMP-9 and Runx2 were close to the limit of detection by quanti-
tative RT-PCR in tissues, we clearly measured a high expression level
of Runx2 and MMP-9 proteins in both intraprostatic IGR-CaP1 tu-
mors (86% and 100%, respectively) and bone metastases (63% and
67%, respectively; Figure 6B).
Taken together, these results show that IGR-CaP1 bone metastases
express a bone metastasis gene signature (Runx2, CXCR4, MMP-9,
HBB, SPP1, ADAMTS14, FGFBP2, and OPG ). These genes were
all expressed in the parental cell line and in the primary tumors, and
their expression was moderately increased in response to the bone
microenvironment. On the basis of the essential role of Runx2 in
bone metastasis, our results suggest that Runx2 may influence both
osteoblastic and osteoclastic activities at the tumor-bone interface by
modulating target genes.
Discussion
In the present study, we used the new prostate cell line IGR-CaP1,
which was derived from primary epithelial PCa that had been previ-
ously characterized in vitro [19]. These cells correspond to androgen-
independent basal epithelial PCa cells that exhibit high levels of cancer
stem cell markers, namely CD44, CD133, and CXCR4. The experi-
ments presented here detail the IGR-CaP1 animal model. IGR-CaP1
tumors grew in nude mice that were either subcutaneously injected
or orthotopically implanted. The growth rate was relatively slow, with
a tumor volume of ∼300 mm3 at 6 weeks after subcutaneous im-
plantation. In contrast with the androgen-independent PC-3 model,
the IGR-CaP1 tumors exhibited glandular acini-like structures and
were highly vascularized with abundant stroma, closely resembling
the prostate adenocarcinoma. We observed expression of prostate-
specific markers, confirming the prostate origin of the intraprostatic
tumors and expression of vimentin, which is seen both in primary
tumors and in metastases, revealing the invasive potential of the tumor
cells. Transduction of these cells with a luciferase- and GFP-expressing
retrovirus allowed the detection of spontaneous metastases in liver,
lung, and/or peritoneum, albeit at a low frequency. Bioluminescence
imaging was used to follow the tumor growth of IGR-CaP1 cells in-
jected into the prostate, bone, or heart. The tumor take, which was
calculated from all the operated mice, was observed in 100% of the
subcutaneous xenografts. We obtained a slightly lower tumor take
depending on the technical difficulties to perform surgery for intra-
prostatic or intracardiac transplantations (84% and 86%, respectively).
Skeletal metastases comprise the major localization of metastatic
spread in PCa. In contrast to most metastatic skeletal lesions, which
are primarily osteolytic in nature, PCa metastases to bone are gen-
erally considered to be osteoblastic and are characterized by deposi-
tion of dense sclerotic bone. The study of the molecular mechanisms
underlying the development of osteoblastic lesions requires cellular
models that can generate osteoblastic lesions in animal models. How-
ever, there are few animal models that recapitulate spontaneous
clinical bone metastases [39]. Among them, the widely used androgen-
independent PC-3 model, for which luciferase-expressing versions are
available, generates pure osteoclastic bone lesions. The fact that bone
lesions generated by PC-3 cells do not include osteoblastic activity is
an obvious limitation of this model. Other models showing osteoblastic
or mixed lytic/blastic lesions when implanted in the bones of immuno-
compromised mice, in particular the LAPC9 and C4-2B models, have
been used to study the complex interactions among the tumor cells
and the bone microenvironment [9,10,40,41]. However, the fact that
LAPC9 does not grow in vitro and needs for continued transplantation
in animals is a limitation of this model. The metastatic potential of the
C4-2B derived subline was artificially obtained by multiple passaging
and cocultures from the LNCaP cell line. To date, the 22RV1 cell line
is the unique cell line generating mixed lytic/osteoblastic bone lesions,
which has been genetically modified to express luciferase, thus allowing
the follow-up of bone lesions by BLI [13,14]. However, the 22RV1
cells were also obtained artificially in vitro from a coculture of the
derived CWR22R subline, which was issued from the CWR22 xeno-
graft [42]. In contrast, the IGR-CaP1 model, directly derived from a
primary PCa, generates mixed lytic/osteoblastic bone lesions. The
limitation of our model consists of the lack of detection of spontaneous
bone metastases from the intraprostatic tumor in nude mice. Because
bone metastases appeared at the late stages of the disease in humans,
we could hypothesize that the time required for the metastatic cell
spreading from the intraprostatic tumor is a long process that cannot
be reached during the time course of this experiment in our animal
model. The use of more immunocompromised host mice, such as
Rag2−/−;γc
−/− mice, could be another option to circumvent this impor-
tant issue. We showed in this study that the IGR-CaP1 model provides
a new model of androgen-independent metastatic PCa that closely
mimics the bone metastases of patients. Bone lesions and large new
bone deposits were confirmed using both CT and quantitative SPECT
imaging modalities. Osteolytic activity was confirmed by the presence
of osteoclasts in the bone lesions. Because the bone lesions derived
after intratibial implantation model may not exhibit the same biologic
activity as bone metastases, intracardiac inoculation of IGR-CaP1 cells
was performed and was shown to generate bone lesions with a mixed
pattern. The IGR-CaP1 preclinical model is therefore a unique model
obtained from a primary prostate tumor, which generates experimental
bone metastasis. The establishment of a bioluminescent version of this
model provides a valuable tool for the study of both intraprostatic and
bone metastatic progression.
Recently, Müller et al. [43] have shown that chemokine receptors
are critical in determining the metastatic destination of tumor cells.
CXCR4 is a well-known chemokine receptor that can trigger metastasis
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in a variety of cancers [44,45], including PCa [46,47]. We showed
previously using FACS analysis that the IGR-CaP1 cells expressed a
high level of CXCR4 protein [19]. This finding is suggestive of the
propensity of IGR-CaP1 cells to metastasize to bone. We have shown
previously that expression of CXCR4 was indeed increased after engraft-
ment in mice and subsequent in vitro culture reestablishment [19]. Pre-
vious studies have shown that CXCR4 expression correlates with the
promotion of metastasis in prostate tumors [47], but contradictory
results were obtained regarding the detection of CXCR4 in prostate
primary tumors and metastases. These conflicting results may be due
to the use of different CXCR4-directed antibodies. We were unable to
detect any relevant signals by immunohistochemistry of CXCR4 in
bone metastases, which may be attributed either to the low quality of
available antibodies or to the decalcification procedure. However, we
detected expression of the CXCR4 gene in human tumor cells after
direct-bone injection, suggesting that the attachment of primary tumor
cells to basement membranes could be enhanced by CXCR4 signaling.
In addition, MMPs have been reported to facilitate cancer cell invasion
and metastasis through degradation of the surrounding extracellular
matrix proteins. MMP expression was increased in malignant breast
and PCa cells, and MMP-2 and MMP-9, in particular, have been asso-
ciated with poor prognosis [48]. Recent results suggested that MMPs
could be downstream targets of CXCR4-mediated signaling [49,50].
Because we observed high levels ofMMP-9 protein in IGR-CaP1 tumors
and bone metastases, our results suggest that MMP-9 expression may
be regulated by CXCR4 expression in our model.
Once established in bone, crosstalk between tumor cells and the bone
microenvironment causes impairment in the remodeling process, caus-
ing metastatic tumor cells to secrete factors that stimulate osteoclast-
mediated bone destruction. Osteoblasts are also intimately involved
in the regulation of osteoclast differentiation via RANKL and OPG ex-
pression. The mechanism through which IGR-CaP1 cells produces
mixed osteoblastic/lytic lesions is not currently defined. However, our
results suggest that the increased expression of OPG and osteopontin
(SPP1) may lead to an overall inhibition of osteoclast activity, resulting
in a shift of bone remodeling toward osteoblastic activity and mineral-
ization of the bone. The role of the HBB, ADAMTS14, and FGFBP2
were less known, but gene expression profiles of PCa comparing ex-
pression levels between metastatic and primary tumor samples showed
increased expression of these genes in metastases [33]. The effects of
the overexpression of HBB and FGFBP2 in tissues compared with
the parental IGR-CaP1 cell line need further investigations.
Runx2, a protein previously known for its master regulatory roles in
the chondro-osteoblast lineage, is now emerging as a prometastatic
transcription factor that may control multiple aspects of metastasis.
Runx2 is expressed in androgen-independent PC-3 cells [51]. A re-
cent study reports that Runx2 is as a key regulator of events associated
with PCa metastatic bone disease by promoting activation of metas-
tatic target genes including VEGF, osteopontin, MMPs, and survivin
[52]. As was previously described in human PCa tissues, we observed
high immunohistochemical expression of Runx2 in aggressive intra-
prostatic tumors and bone metastases. The high expression of Runx2
protein in bone metastases in the IGR-CaP1 preclinical model sug-
gests that Runx2 might be implicated in the regulation of osteopontin
and MMP-9. Our results suggest that the Runx2-mediated path-
way may be implicated in the osteoblastic properties of the IGR-CaP1
bone lesions.
This article describes a new preclinical model of PCa in immuno-
compromised mice, which experimentally reproduces the widespread
bone metastasis with mixed osteolytic/blastic lesions that is often
observed in patients. Dynamic monitoring was used to follow the
metastatic dissemination using noninvasive bioluminescence, CT,
and quantitative SPECT imaging modalities. We also provided an ex-
pression signature for the responsiveness of IGR-CaP1 cells to the bone
microenvironment, namely CXCR4, MMP-9, Runx2, osteopontin,
OPG, ADAMTS14, FGFBP2, and HBB expression, suggesting that a
combination of therapeutic approaches for targeting both osteoblasts
and osteoclasts may be beneficial in limiting the progression of estab-
lished bone metastasis. Therefore, the IGR-CaP1 model is one of the
few suitable models for preclinical studies providing osteosclerotic bone
changes and for in vitro studies in tissue culture and three-dimensional
spheroids. The up-regulation of the proteins corresponding to the bone
metastasis signature suggests potential targets for reversing bone metas-
tasis; these mechanisms could be studied using the IGR-CaP1 pre-
clinical model to elucidate drug targets with potential clinical relevance.
Acknowledgments
The authors thank S. Cotteret for the critical reading of the article
and J.L. Villeval, J.P. Morgenstern, and X. Xiong for the kind gift
of the luciferase-GFP expression retroviral vector. The authors also
thank J. Sobilo and S. Retif for technical help, G. Reveillon for his
help with the CT and SPECT quantifications, and F. Commo for
his help with the statistical analysis.
References
[1] Jemal A, Siegel R, Xu J, and Ward E (2010). Cancer statistics, 2010. CA Cancer
J Clin 60, 277–300.
[2] Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ,
Davis B, and Blute ML (2002). Metastatic prostate carcinoma to bone: clini-
cal and pathologic features associated with cancer-specific survival. Cancer 95,
1028–1036.
[3] Mundy GR (2002). Metastasis to bone: causes, consequences and therapeutic
opportunities. Nat Rev Cancer 2, 584–593.
[4] Roodman GD (2004). Mechanisms of bone metastasis. N Engl J Med 350,
1655–1664.
[5] Jin J-K, Dayyani F, and Gallick GE (2011). Steps in prostate cancer progression
that lead to bone metastasis. Int J Cancer 128, 2545–2561.
[6] Seibel MJ (2005). Clinical use of markers of bone turnover in metastatic bone
disease. Nat Clin Pract Oncol 2, 504–517.
[7] Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S,
Mullins C, Fridman R, and Cher ML (2002). Matrix metalloproteinase activ-
ity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone
metastasis. J Natl Cancer Inst 94, 17–25.
[8] Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, Yang H, Zhau
HE, Balian G, and Chung LW (1998). Establishing human prostate cancer cell
xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-
producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived
metastatic sublines. Int J Cancer 77, 887–894.
[9] Hall CL, Bafico A, Dai J, Aaronson SA, and Keller ET (2005). Prostate cancer cells
promote osteoblastic bone metastases through Wnts. Cancer Res 65, 7554–7560.
[10] Hsu WK, Virk MS, Feeley BT, Stout DB, Chatziioannou AF, and Lieberman
JR (2008). Characterization of osteolytic, osteoblastic, and mixed lesions in
a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT. J Nucl
Med 49, 414–421.
[11] Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR,
and Vessella RL (2002). Establishment and characterization of osseous prostate
cancer models: intra-tibial injection of human prostate cancer cells. Prostate 52,
20–33.
[12] Lee Y-P, Schwarz EM, Davies M, Jo M, Gates J, Zhang X, Wu J, and
Lieberman JR (2002). Use of zoledronate to treat osteoblastic versus osteolytic
lesions in a severe-combined–immunodeficient mouse model. Cancer Res 62,
5564–5570.
[13] Henry MD, Silva MD, Wen S, Siebert E, Solin E, Chandra S, and Worland PJ
(2005). Spiculated periosteal response induced by intraosseous injection of 22Rv1
386 IGR-CaP1 Is a Preclinical Model of Prostate Cancer Al Nakouzi et al. Neoplasia Vol. 14, No. 5, 2012
prostate cancer cells resembles subset of bone metastases in prostate cancer patients.
Prostate 65, 347–354.
[14] Drake JM, Gabriel CL, and Henry MD (2005). Assessing tumor growth and
distribution in a model of prostate cancer metastasis using bioluminescence
imaging. Clin Exp Metastasis 22, 674–684.
[15] Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, and
Navone NM (2004). High efficacy of docetaxel with and without androgen
deprivation and estramustine in preclinical models of advanced prostate cancer.
Anticancer Res 24, 2897–2903.
[16] Kundra V, Ng CS, Ma J, Bankson JA, Price RE, Cody DD, Do K-A, Han L,
and Navone NM (2007). In vivo imaging of prostate cancer involving bone in a
mouse model. Prostate 67, 50–60.
[17] Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, and McCauley LK
(2009). A destructive cascade mediated by CCL2 facilitates prostate cancer
growth in bone. Cancer Res 69, 1685–1692.
[18] Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, and
McCauley LK (2005). Bone turnover mediates preferential localization of pros-
tate cancer in the skeleton. Endocrinology 146, 1727–1736.
[19] Chauchereau A, Al Nakouzi N, Gaudin C, Le Moulec S, Compagno D, Auger N,
Bénard J, Opolon P, Rozet F, Validire P, et al. (2011). Stemness markers charac-
terize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer.
Exp Cell Res 317, 262–275.
[20] Morgenstern JP and Land H (1990). Advanced mammalian gene transfer: high
titre retroviral vectors with multiple drug selection markers and a complementary
helper-free packaging cell line. Nucleic Acids Res 18, 3587–3596.
[21] Singh AS and Figg WD (2005). In vivo models of prostate cancer metastasis to
bone. J Urol 174, 820–826.
[22] Rössler J, Monnet Y, Farace F, Opolon P, Daudigeos-Dubus E, Bourredjem A,
Vassal G, and Geoerger B (2011). The selective VEGFR1-3 inhibitor axitinib
(AG-013736) shows antitumor activity in human neuroblastoma xenografts.
Int J Cancer 128, 2748–2758.
[23] Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, and Moul JW (1998).
CD34 immunohistochemical assessment of angiogenesis as a prognostic marker
for prostate cancer recurrence after radical prostatectomy. J Urol 160, 459–465.
[24] Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AAG, Villette
J-M, Stower MJ, and Maitland NJ (2002). Enhanced expression of vimentin
in motile prostate cell lines and in poorly differentiated and metastatic prostate
carcinoma. Prostate 52, 253–263.
[25] Kessenbrock K, Plaks V, and Werb Z (2010). Matrix metalloproteinases: regu-
lators of the tumor microenvironment. Cell 141, 52–67.
[26] Zhang L, Shi J, Feng J, Klocker H, Lee C, and Zhang J (2004). Type IV colla-
genase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer
Prostatic Dis 7, 327–332.
[27] Trudel D, Fradet Y, Meyer F, and Têtu B (2010). Matrix metalloproteinase 9 is
associated with Gleason score in prostate cancer but not with prognosis. Hum
Pathol 41, 1694–1701.
[28] Yi B, Williams PJ, Niewolna M, Wang Y, and Yoneda T (2002). Tumor-derived
platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metas-
tasis in an animal model of human breast cancer. Cancer Res 62, 917–923.
[29] Uematsu T, Yuen S, Yukisawa S, Aramaki T, Morimoto N, Endo M, Furukawa H,
Uchida Y, and Watanabe J (2005). Comparison of FDG PET and SPECT for de-
tection of bone metastases in breast cancer. AJR Am J Roentgenol 184, 1266–1273.
[30] Kanishi D (1993). 99mTc-MDP accumulation mechanisms in bone. Oral Surg
Oral Med Oral Pathol 75, 239–246.
[31] Cawthorn TR, Amir E, Broom R, Freedman O, Gianfelice D, Barth D, Wang
D, Holen I, Done SJ, and Clemons M (2009). Mechanisms and pathways of
bone metastasis: challenges and pitfalls of performing molecular research on
patient samples. Clin Exp Metastasis 26, 935–943.
[32] Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C,
Guise TA, and Massagué J (2003). A multigenic program mediating breast
cancer metastasis to bone. Cancer Cell 3, 537–549.
[33] Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W,
Michalopoulos G, Becich M, and Monzon FA (2007). Gene expression profiles
of prostate cancer reveal involvement of multiple molecular pathways in the
metastatic process. BMC Cancer 7, 64.
[34] Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, and Rabbani SA (2006).
Expression of RANKL/RANK/OPG in primary and metastatic human pros-
tate cancer as markers of disease stage and functional regulation. Cancer 107,
289–298.
[35] Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH, Morris MD, and
Keller ET (2001). Bone metastatic LNCaP-derivative C4-2B prostate cancer
cell line mineralizes in vitro. Prostate 47, 212–221.
[36] Ding Z, Wu C-J, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu
X, Lis R, et al. (2011). SMAD4-dependent barrier constrains prostate cancer
growth and metastatic progression. Nature 470, 269–273.
[37] Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P,
Gitelman I, Richardson A, and Weinberg RA (2004). Twist, a master regulator of
morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927–939.
[38] Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, and Stein GS
(2006). Regulatory roles of Runx2 in metastatic tumor and cancer cell inter-
actions with bone. Cancer Metastasis Rev 25, 589–600.
[39] Chauchereau A (2011). Experimental models for the development of new medical
treatments in prostate cancer. Eur J Cancer 47(suppl 3), S200–S214.
[40] Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, Huard J, and
Lieberman JR (2005). Influence of BMPs on the formation of osteoblastic
lesions in metastatic prostate cancer. J Bone Miner Res 20, 2189–2199.
[41] Lee Y, Schwarz E, Davies M, Jo M, Gates J, Wu J, Zhang X, and Lieberman JR
(2003). Differences in the cytokine profiles associated with prostate cancer cell
induced osteoblastic and osteolytic lesions in bone. J Orthop Res 21, 62–72.
[42] Sramkoski RM, Pretlow TG II, Giaconia JM, Pretlow TP, Schwartz S, Sy MS,
Marengo SR, Rhim JS, Zhang D, and Jacobberger JW (1999). A new human
prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35, 403–409.
[43] Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T,
Murphy E, Yuan W, Wagner SN, et al. (2001). Involvement of chemokine
receptors in breast cancer metastasis. Nature 410, 50–56.
[44] Burger JA and Kipps TJ (2006). CXCR4: a key receptor in the crosstalk between
tumor cells and their microenvironment. Blood 107, 1761–1767.
[45] Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek
A, Ratajczak J, and Ratajczak MZ (2005). Trafficking of normal stem cells and
metastasis of cancer stem cells involve similar mechanisms: pivotal role of the
SDF-1–CXCR4 axis. Stem Cells 23, 879–894.
[46] Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, and McCauley
LK (2002). Use of the stromal cell–derived factor-1/CXCR4 pathway in pros-
tate cancer metastasis to bone. Cancer Res 62, 1832–1837.
[47] Sun Y-X, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman NI,
Koh-Paige AJ, Shim H, et al. (2005). Skeletal localization and neutralization of
the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth
in osseous sites in vivo. J Bone Miner Res 20, 318–329.
[48] Chabottaux V and Noel A (2007). Breast cancer progression: insights into multi-
faceted matrix metalloproteinases. Clin Exp Metastasis 24, 647–656.
[49] Yu T,Wu Y, Helman JI, Wen Y, Wang C, and Li L (2011). CXCR4 promotes oral
squamous cell carcinoma migration and invasion through inducing expression of
MMP-9 andMMP-13 via the ERK signaling pathway.Mol Cancer Res 9, 161–172.
[50] Wang Q, Diao X, Sun J, and Chen Z (2011). Regulation of VEGF, MMP-9, and
metastasis by CXCR4 in a prostate cancer cell line. Cell Biol Int 35, 897–904.
[51] Yeung F, Law WK, Yeh C-H, Westendorf JJ, Zhang Y, Wang R, Kao C, and
Chung LWK (2002). Regulation of human osteocalcin promoter in hormone-
independent human prostate cancer cells. J Biol Chem 277, 2468–2476.
[52] Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van
Wijnen AJ, Stein JL, Languino LR, Altieri DC, et al. (2010). Runx2 association
with progression of prostate cancer in patients: mechanisms mediating bone
osteolysis and osteoblastic metastatic lesions. Oncogene 29, 811–821.
Neoplasia Vol. 14, No. 5, 2012 IGR-CaP1 Is a Preclinical Model of Prostate Cancer Al Nakouzi et al. 387
Figure W1. HES staining of the bone lesions obtained after a direct injection into the tibia showing bone remodeling. (A and B) Osteoclasts
(arrows). (C and D) Osteoblasts (arrows).
Figure W2. HES staining of the bone lesions obtained after injection
of tumor cells into the left ventricle. Arrows show the presence of
osteoclasts in the bone lesions.
